$Novavax (NVAX.US)$ which is facing an inordinate delay in g...

$Novavax (NVAX.US)$ which is facing an inordinate delay in getting authorization for its COVID-19 vaccine, are moving sharply lower Wednesday.Amid the delay in authorization, reports suggest the company is facing issues with the purity of the vaccine candidate.The study showed that NVX-CoV2373 was well tolerated and generated a robust immune response when given as the second dose in a mixed or heterologous regimen after either $AstraZeneca (AZN.US)$ and $Pfizer (PFE.US)$ $BioNTech (BNTX.US)$ vaccine as the first dose.